Company news

Mayne Pharma Group Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Mayne Pharma May 2023 market update presentation

May 9, 2023

MYX completes sale of US retail generics business for US$90m

April 10, 2023

Update on sale of US retail generics portfolio

April 2, 2023

Mayne Pharma announces cancellation of capital return

February 27, 2023

2023 Half Year Investor Presentation

February 27, 2023

2022 Half Year Media Release

February 27, 2023

Mayne Pharma announces sale of US retail generics business

February 27, 2023

Mayne Pharma to restate US dermatology net revenue for FY22

February 14, 2023

Mayne Pharma and Mithra announce US launch of HALOETTE, a generic version of NUVARING

January 16, 2023

Mayne Pharma provides update on capital management timeline

January 11, 2023

MYX completes TherapeuticsMD product licensing transaction

January 2, 2023

MYX signs license agreement for womens health products

December 4, 2022

AGM presentation and business and trading update

November 29, 2022

Return of Capital - MYX

October 27, 2022

Dividend/Distribution - MYX

October 27, 2022

Mayne Pharma capital management update

October 27, 2022

Mayne Pharma completes sale of Metrics Contract Services

October 5, 2022

Mayne Pharma completes sale of Metrics Contract Services

October 4, 2022

Mayne Pharma - appointment of chief executive officer and Managing Director

September 29, 2022

Mayne Pharma appoints new CEO

September 27, 2022

Mayne Pharma Group - non-executive Director appointment and retirement

August 31, 2022

2022 Full Year Investor Presentation

August 25, 2022

2022 Full Year Media Release

August 25, 2022

Appendix 4E and Statutory Accounts

August 25, 2022

Mayne Pharma Group: CEO announces plan to retire

August 19, 2022

Mayne Pharma CEO announces plan to retire

August 18, 2022

Mayne Pharma announces sale of Metrics Contract Services

August 9, 2022

Mayne Pharma and Mithra announce FDA approval of Haloette, a generic version of Nuvaring

August 7, 2022

Mayne Pharma and GoodRx announce new initiative to increase awareness of NEXTSTELLIS and expand access to birth control

August 1, 2022

Mayne Pharma Group Limited and Mithra Pharmaceuticals - NEXTSTELLIS ORAL CONTRACEPTIVE NOW AVAILABLE IN AUSTRALIA

July 27, 2022

New Chief Financial Officer appointment

July 21, 2022

Wilsons investor conference presentation

May 25, 2022

Mayne Pharma recipient of $4.8m Federal Government Grant

May 9, 2022

Mayne Pharma Group Limited - NON-EXECUTIVE DIRECTOR APPOINTMENT

March 22, 2022

22/03/2022 Non Executive Director Appointment

March 21, 2022

Mayne Pharma reports 1HFY22 results

February 28, 2022

2022 Half Year Investor Presentation

February 24, 2022

Mayne Pharma expands US dermatology portfolio

February 10, 2022

2021 Mayne Pharma AGM Speeches

November 22, 2021

2021 Full Year Media Release

August 26, 2021

2021 Full Year Investor Presentation

August 26, 2021

Class action proceeding

August 2, 2021

FDA approval of novel oral contraceptive NEXTSTELLIS

April 15, 2021

2021 Half Year Investor Presentation

February 23, 2021

2021 Half Year Media Release

February 23, 2021

Chairman and CEOs Addresses to Shareholders

November 23, 2020

Mayne Pharma provides update on Womens Health pipeline

October 5, 2020

2020 Full Year Investor Presentation

August 20, 2020

2020 Full Year Media Release

August 20, 2020

Mayne Pharma announces strategic partnership with Novast

July 5, 2020

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 90 decks. Every deck is listed under its year.